Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patient-Driven Drug Development Requires New Transparency Policies

Executive Summary

If advocacy groups are going to play a greater role in drug development, they need more access to sponsors' data and interactions with the US FDA, and more information about how the agency uses patient preference data, Parent Project Muscular Dystrophy rep says.


Related Content

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Trump’s FDA Reform Agenda: Patient-Focused Approvals
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances
Duchenne Group's Presentation Is Milestone For Patient Involvement
FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts